Well, there's that old saying about any big project: you can have it on time, under budget, and done well. Pick two.
This is a revolutionary drug that's consistently shown to be safe. Management has met their objectives. But behind schedule on every count. So we know which objectives management has chosen.
But we shouldn't make perfect the enemy of good. They were a year behind on the IND. They've taken at least an extra 6 months with every single trial. They haven't been good about communicating why things have taken long. But it also appears their caution has been a factor in the progress.
Management is clearly not rushing Scenesse to market. I feel that extra caution will increase the chance of EMEA and FDA approval. I hope they will get many questions about the timeline at the AGM and I hope Wolgen will take the opportunity to be candid about the delays and give any explanation
CUV Price at posting:
$1.85 Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)